Páll A, Becs G, Erdei A, Sira L, Czifra A, Barna S, Kovács P, Páll D, Pfliegler G, Paragh G, Szabó Z (2014). "Pseudopheochromocytoma induced by anxiolytic withdrawal". European Journal of Medical Research. 19: 53. doi:10.1186/s40001-014-0053-9. PMC 4196012. PMID 25288254. External links
GPnotebook entry
Side effects
Dry mouth, urinary retention, headaches, vomiting, diarrhea, constipation, blurry vision are possible side effects of the medication. Since glycopyrronium reduces the bodys sweating ability, it can even cause hyperthermia and heat stroke in hot environments. The medication also induces drowsiness, an effect exacerbated by the consumption of alcohol. Pharmacology
Mechanism of action
Glycopyrronium competitively blocks muscarinic receptors, thus inhibiting cholinergic transmission. Pharmacokinetics
Glycopyrronium bromide affects the gastrointestinal tracts, liver and kidney but has a very limited effect on the brain and the central nervous system. In horse studies, after a single intravenous infusion, the observed tendencies of glycopyrronium followed a tri-exponential equation, by rapid disappearance from the blood followed by a prolonged terminal phase. Excretion was mainly in urine and in the form of an unchanged drug. Glycopyrronium has a relatively slow diffusion rate, and in a standard comparison to atropine, is more resistant to penetration through the blood-brain barrier and placenta. Research
It has been studied in asthma. References
External links
"Glycopyrronium bromide". Drug Information Portal. U.S. National Library of Medicine. "Glycopyrronium". Drug Information Portal. U.S. National Library of Medicine.